EDMONTON, ALBERTA (September 25, 2020) – 48Hour Discovery Inc. announced today that it has filed a US provisional patent that describes a novel method for treatment of COVID-19. The provisional patent entitled: “Novel Methods of Treating Betacoronavirus Infections and Related Disorders” (U.S. Provisional Application No. 63/047,580) was filed in July.
Earlier this year 48Hour Discovery Inc. initiated drug discovery projects for therapeutic targets related to COVID-19. 48Hour Discovery Inc. is using its proprietary technology to rapidly identify and optimize peptide drug candidates for use as anti-viral treatments for those infected with COVID-19
“We are excited to have discovered such potent compounds so quickly,” explained John Dwyer, Vice President of Research at 48Hour Discovery. Dwyer also worked on similar drug discovery programs during the SARS outbreak in 2003, he also said: “Our goal is to have clinically attractive compounds ready for pre-clinical testing within twelve months.”
About 48Hour Discovery Inc.
48Hour Discovery Inc. is a University of Alberta biotechnology spin-off company that develops peptide-based therapeutic drugs from billion-scale libraries of molecules. It uses phage display and high throughput next-generation sequencing (NGS) to identify peptide ligands with high affinity for promising drug targets. Founded in 2017, 48Hour Discovery Inc. has a number of peptide discovery projects underway, including contracts with five of the top pharmaceutical companies in the world. For more information, visit https://staging.48hourdiscovery.com.
Contacts
David Alton
VP Finance and Business Development
48Hour Discovery Inc.
dalton@staging.48hourdiscovery.com
780-938-9207
John Dwyer
VP Research
48Hour Discovery Inc.
jdwyer@staging.48hourdiscovery.com
